Sign In
Buy TCRX
$0.743
-0.0127 (-1.68%)
At Close: Jul 31, 2026
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
04:05pm, Wednesday, 03'rd Dec 2025
WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
09:26am, Wednesday, 12'th Nov 2025
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.25 per share a year ago.
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Wednesday, 12'th Nov 2025
Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA ™ Phase 1 heme trial to be presented at the 67 th American Society of Hema
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
07:00am, Wednesday, 05'th Nov 2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritiz
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
07:00am, Wednesday, 17'th Sep 2025
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimm
TScan Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 03'rd Sep 2025
WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
04:01pm, Tuesday, 12'th Aug 2025
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.28 per share a year ago.
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 12'th Aug 2025
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalen
Squarepoint Ops LLC Makes New $59,000 Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure w
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
07:00am, Wednesday, 28'th May 2025
WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Tuesday, 06'th May 2025
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 06'th May 2025
Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the secon
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
04:53pm, Monday, 28'th Apr 2025
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
